Convergent Therapeutics
Cambridge
About Convergent Therapeutics
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV 01-╬▒, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV 01-╬▒ is that, once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into the prostate cancer cells. CONV 01-╬▒ is covered by multiple issued U.S. and foreign patents. If FDA-approved, CONV 01-╬▒ would be the first antibody approved to direct a radioisotope to prostate cancer and the first drug approved for the use of 225Ac in a cancer treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $130.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2024)
- Website: convergentrx.com
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/convergent-therapeutics-25687 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.